Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-04-29
2003-12-09
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S639000, C514S246000, C514S300000, C514S313000, C514S349000, C514S646000, C514S367000
Reexamination Certificate
active
06660737
ABSTRACT:
TECHNICAL FIELD
This invention is directed to compounds that are useful in methods of treating hypoxia related disorders. The invention is also directed to pharmaceutical compositions comprising the compounds.
REFERENCES:
patent: 4997835 (1991-03-01), Schaper et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5882914 (1999-03-01), Semenza
patent: 5942527 (1999-08-01), Kadaba et al.
patent: 5985913 (1999-11-01), Williams et al.
patent: 6020462 (2000-02-01), Semenza
patent: 6329378 (2001-12-01), Mei et al.
patent: 0315434 (1989-05-01), None
patent: 44020090 (1969-08-01), None
patent: WO 88/00047 (1988-01-01), None
patent: WO 97/15308 (1997-05-01), None
patent: WO 98/17267 (1998-04-01), None
patent: WO 00/10578 (2000-03-01), None
patent: WO 01/72718 (2001-10-01), None
patent: WO 02/16315 (2002-02-01), None
Bun et al., “Oxygen Sensing and Molecular Adaptation of Hypoxia”,Amer. Physiological Society, 1996, pp. 839-885, vol. 76, No. 3.
Semenza, “Regulation of Mammalian O2Homeostasis by Hypoxia-Inducible Factor 1.”,Annu. Rev. Cell Dev. Biol., 1999, pp. 551-578, vol. 15.
Shweiki et al., “Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis”,Proc. Natl., Acad. Sci., 1995, pp. 768-772, vol. 92.
Semenza, “HIF-1: mediator of physiological and pathophysiological responses to hypoxia”,J. Appl. Physiol., 2000, pp. 1474-1480, vol. 88.
Semenza, “Hypoxia-inducible factor 1: master regularor of O2homeostasis”,Genetics&Development, 1998, pp. 588-594, vol. 8.
Jiang et al., “Transactivation and inhibitory domanins of hypoxia-inducible facter 1&agr;”,J. Biol. Chem., 1997, pp. 19253-19260, vol. 272, No. 31.
Jiang et al., “Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1”,J. of Biol. Chem., 1996, pp. 17771-17778, Vol 271, No. 30.
Pearlman et al., “Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis”,Nature Medicine, 1995, pp. 1085-1089, vol. 1, No. 10.
Takeshita et al., “A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model”,J. Clin. Invest., 1994, pp. 662-670, vol. 93.
Hendel et al., “Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion”,Circulation, 2000, pp. 118-121, vol. 101, No. 2.
Schwartz et al., “Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction mdoel in the rat—angiogenesis and angioma formation”,J. Amer. College of Cardiology, 2000, pp. 1323-1330, vol. 35, No. 5.
Shweiki et al., “Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis”,Letters to Nature, 1992, pp. 843-845, vol. 359.
Levy et al., “Transcriptional regulation of the rat vascular endothelial growth facror gene by hypoxia”,Drug Disc. Today, 1995, pp. 13333-13340, vol. 270, No. 22.
Ikeda et al., “Hypoxia-induced transcriptional activaiton and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells”,J. Biol. Chem., 1995, pp. 19761-19766, vol. 270, No. 34.
Levy et al., “Post-transcriptional regualtion of vascular endothelial growth factor by hypoxia”,Drug Disc Today, 1996, pp. 2746-2753, vol. 271, No. 5.
Agani et al., “Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity”,Mol. Pharmacol., 1998, pp. 749-754, vol. 54.
Brogi et al., “Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregualtes VEGF expresssion only”,Ciruclation, 1994, pp. 649-652, vol. 90.
Van Belle et al., “Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor”,Circulation, 1998, pp. 381-390, vol. 97, No. 4.
Semenza, “Regulation of erythropoietin production”,Hematol. Oncol., Clin. N. Amer., 1994, pp. 863-885, vol. 8, No. 5.
Semenza et al., “Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1”,J. Biol. Chem., 1994, pp. 23757-23763, vol. 269, No. 38.
Kranz, “Blood”,J. of Amer. Society of Hematology, 1991, pp. 419-434, vol. 77, No. 3.
Quroshi et al., “Minicry of erythropoietin by a nonpeptide molecule”,PNAS, 1999, pp. 12156-12161, vol. 96, No. 21.
Almstead Ji-In Kim
Izzo Nicholas John
Jones David Robert
Kawamoto Richard Masaru
Fay Zohreh
Kwon Brian-Yong S.
The Procter & Gamble & Company
Upire David V.
LandOfFree
Medicinal uses of hydrazones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal uses of hydrazones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal uses of hydrazones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3118649